相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Efficient extravasation of tumor-repopulating cells depends on cell deformability
Junjian Chen et al.
SCIENTIFIC REPORTS (2016)
FDA-approved small-molecule kinase inhibitors
Peng Wu et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Curcumin enhances the production of major structural components of elastic fibers, elastin, and fibrillin-1, in normal human fibroblast cells
Shu-Mei Lee et al.
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY (2015)
Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis
Dongshi Chen et al.
CLINICAL CANCER RESEARCH (2014)
Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo
Yanxia Zhao et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Aurora Kinase Inhibition Induces PUMA via NF-κB to Kill Colon Cancer Cells
Jing Sun et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Crizotinib Induces PUMA-Dependent Apoptosis in Colon Cancer Cells
Xingnan Zheng et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Substrate and Inhibitor Specificity of the Type II p21-Activated Kinase, PAK6
Jia Gao et al.
PLOS ONE (2013)
On DABAL-Me3 promoted formation of amides
Nathalie Dubois et al.
TETRAHEDRON (2013)
Positron emission tomography imaging of tumor angiogenesis and monitoring of antiangiogenic efficacy using the novel tetrameric peptide probe 64Cu-cyclam-RAFT-c(-RGDfK-)4
Zhao-Hui Jin et al.
ANGIOGENESIS (2012)
Radioiodinated sunitinib as a potential radiotracer for imaging angiogenesis-radiosynthesis and first radiopharmacological evaluation of 5-[125I]Iodo-sunitinib
Manuela Kuchar et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth
C. Dudgeon et al.
ONCOGENE (2012)
AlMe3-Promoted Formation of Amides from Acids and Amines
Jianqing Li et al.
ORGANIC LETTERS (2012)
Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors
Michele McTigue et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation
Woo-Jin Jeong et al.
CANCER BIOLOGY & THERAPY (2011)
Suppression of SOCS3 increases susceptibility of renal cell carcinoma to interferon-alpha
Shintaro Tomita et al.
CANCER SCIENCE (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Synthesis and Biological Evaluation of 3-Substituted-indolin-2-one Derivatives Containing Chloropyrrole Moieties
Yun-Zhou Jin et al.
MOLECULES (2011)
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
Theonie Anastassiadis et al.
NATURE BIOTECHNOLOGY (2011)
Novel Potent Orally Active Multitargeted Receptor Tyrosine Kinase Inhibitors: Synthesis, Structure-Activity Relationships, and Antitumor Activities of 2-Indolinone Derivatives
Tang Peng Cho et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Discovery of Pyrrole-Indoline-2-ones as Aurora Kinase Inhibitors with a Different Inhibition Profile
Chao-Cheng Chiang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Targeting Angiogenesis with Multitargeted Tyrosine Kinase Inhibitors in the Treatment of Non-Small Cell Lung Cancer
Giorgio Scagliotti et al.
ONCOLOGIST (2010)
5-Substituted pyrido[2,3-d]pyrimidine, an inhibitor against three receptor tyrosine kinases
Naparat Kammasud et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
FerriBRIGHT: A Rationally Designed Fluorescent Probe for Redox Active Metals
Daniel P. Kennedy et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2009)
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients
Ketan S. Gajiwala et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang et al.
NATURE REVIEWS CANCER (2009)
Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor
Robert Roskoski
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Food and drug administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma
Edwin P. Rock et al.
ONCOLOGIST (2007)
Amide bond formation using an air-stable source of AlMe3
Andrew Novak et al.
TETRAHEDRON LETTERS (2006)
Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling
K Godl et al.
CANCER RESEARCH (2005)
Direct and indirect reductive amination of aldehydes and ketones with solid acid-activated sodium borohydride under solvent-free conditions
BT Cho et al.
TETRAHEDRON (2005)
Potent and selective aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition
D Fancelli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Concise syntheses of the cruciferous phytoalexins brassilexin, sinalexin, wasalexins, and analogues: Expanding the scope of the Vilsmeier formylation
MSC Pedras et al.
JOURNAL OF ORGANIC CHEMISTRY (2005)
Readily synthesized novel fluorescent dipyrrinones
SE Boiadjiev et al.
JOURNAL OF ORGANIC CHEMISTRY (2005)
Angiogenesis: basic pathophysiology and implications for disease
DC Felmeden et al.
EUROPEAN HEART JOURNAL (2003)
Discovery of 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase
L Sun et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Angiogenesis modulation in cancer research: Novel clinical approaches
M Cristofanilli et al.
NATURE REVIEWS DRUG DISCOVERY (2002)
Identification of substituted 3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rβ tyrosine kinases
L Sun et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)